| Theme | Clinical research in the field of CKD-MBD | |
|---|---|---|
| Title | Cinacalcet hydrochloride | |
| Publish Date | 2014/10 | |
| Author | Hirotaka Komaba | Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine / Department of Oral Medicine, Infection, and Immunity, Harvard School of Dental Medicine |
| Author | Masafumi Fukagawa | Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine |
| [ Summary ] | The development of cinacalcet hydrochloride has revolutionized the treatment of secondary hyperparathyroidism in patients undergoing dialysis. The effectiveness of cinacalcet in the treatment of secondary hyperparathyroidism has been well established in many clinical trials and observational studies. Recent data suggest that cinacalcet is effective even for patients with severe disease for whom parathyroidectomy has been indicated. More recent clinical trials suggest the potential of cinacalcet to Summary attenuate progression of vascular calcification and to reduce the risk of cardiovascular events, mortality, and bone fractures. It is hoped that such emerging evidence will be adopted for clinical practice and translate into improved outcomes for patients undergoing dialysis. | |